Results

Onemednet Corporation

11/16/2026 | Press release | Distributed by Public on 11/16/2026 15:53

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company's consolidated financial statements and related notes included elsewhere in this Report and in the Form 10-K.

In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading "Cautionary Note Regarding Forward-Looking Statements." Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under "Risk Factors" included elsewhere (or incorporated by reference) in this Report and in the Form 10-K. Unless the context otherwise requires, references in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" to "OneMedNet", "we", "us", "our," and "the Company" are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the completion of the business combination on November 7, 2023 involving OneMedNet Solutions Corporation (formerly named OneMedNet Corporation) ("Legacy ONMD"), with Legacy ONMD surviving as a wholly owned subsidiary of Data Knights Acquisition Corp. ("Data Knights") (the "Business Combination").

Company Overview

We are a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through our proprietary iRWD™ platform and network of healthcare providers, we provide pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.

Our platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. We combine our technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.

Reverse Stock Split

At the Company's 2026 annual meeting of stockholders held on September 18, 2026, the Company's stockholders approved a proposal to effect a reverse stock split of the Company's common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.

On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001 per share ("Common Stock") (the "Reverse Stock Split"). As a result of the Reverse Stock Split, every 10 shares of the Company's Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company's equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split.

All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company's outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.

Nasdaq Compliance

On April 14, 2026, the Company received notice from The Nasdaq Stock Market ("Nasdaq") indicating that the Company, based on the closing bid price of the shares of Common Stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Rule. To regain compliance, the minimum bid price of the shares of Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period.

On October 13, 2026, we received a letter from Nasdaq notifying us that we had regained compliance with the Bid Price Rule and accordingly, the matter is now closed.

Key Components of Consolidated Statements of Operations

Revenue

The Company generates revenue from its iRWD platform, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered and accepted by the customer. The Company's legacy BEAM platform was decommissioned in May 2025, and no revenue was generated from this platform thereafter.

The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advance billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

Cost of Revenue

Our cost of revenue consists primarily of (i) software and hosting costs associated with operating our real-world data platform, (ii) data costs, which include amounts paid to data partners to acquire the clinical and imaging data we deliver to customers, and (iii) personnel costs for employees directly involved in curating and delivering data.

General and Administrative

General and administrative functions include finance, legal, operations, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.

Research and Development

Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.

Sales and Marketing

Our sales and marketing costs consist of labor and tradeshow costs.

Other (Income) Expenses, Net

Interest Expense

Interest expense consists of interest incurred on our outstanding debt facilities, including loans with related parties, deferred underwriter fees and insurance premiums paid in exchange for a note payable.

Change in Fair Value of Warrants

We have outstanding warrants that were issued at the closing of the Business Combination, which are accounted for as liabilities at fair value. These warrants are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations.

Change in Fair Value of Convertible Notes

We have elected the fair value option of accounting for the PIPE Notes (as defined in the Form 10-K) issued in the Business Combination and the Yorkville Note (as defined in the Form 10-K) issued with the 2024 SEPA. These instruments contained embedded derivatives that would require bifurcation and separate accounting; therefore, we made the election to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These instruments are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations. The PIPE Notes and Yorkville Note were both settled in 2025 and were no longer outstanding as of December 31, 2025.

Change in Fair Value of Crypto Assets - Bitcoin

We previously adopted a Bitcoin strategy on the balance sheets as a forward-looking approach to corporate treasury management that incorporates digital currencies. Our Bitcoin holdings were held at fair value on the consolidated balance sheets and are re-measured at the end of each reporting period based on the quoted end-of-day price provided by a reputable and liquid exchange. As of September 30, 2026, we no longer hold Bitcoin or any other crypto assets.

Realized Loss (Gain) on Sale of Crypto Assets - Bitcoin

As part of our Bitcoin strategy, we routinely sell quantities held as part of our corporate treasury strategy to fund operations as needed. We recognize a realized gain upon sale when the price of Bitcoin is higher than its initial purchase price.

Change in Fair Value of SEPA Derivative Liabilities

We entered into the 2024 SEPA and 2026 SEPA, which provide us with the right, but not the obligation, to require Yorkville to purchase shares of our Common Stock during the respective commitment periods, subject to certain limitations. We recognize a put option liability upon execution of each SEPA and a forward option liability upon delivery of a notice to sell shares of our Common Stock. These derivative liabilities are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in our consolidated statements of operations.

Results of Operations

Comparison of the Three Months Ended September 30, 2026 and 2025

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

Three Months Ended September 30, Change
2026 2025 $ %
Revenue
Data delivery revenue 1,023 177 846 478 %
Total revenue 1,023 177 846 478 %
Cost of revenue 1,386 399 987 247 %
Gross margin (363 ) (222 ) (141 ) 64 %
Operating expenses
General and administrative 1,185 1,386 (201 ) -15 %
Sales and marketing 262 304 (42 ) -14 %
Research and development 424 323 101 31 %
Total operating expenses 1,871 2,013 (142 ) -7 %
Loss from operations (2,234 ) (2,235 ) 1 -0 %
Other (income) expense, net
Interest expense 8 6 2 33 %
Change in fair value of warrants (19 ) 20 (39 ) -195 %
Change in fair value of crypto assets - Bitcoin - (55 ) 55 -100 %
Realized gain on sale of crypto assets - Bitcoin - (54 ) 54 -100 %
Change in fair value of 2024 SEPA derivative liabilities - 402 (402 ) -100 %
Change in fair value of 2026 SEPA derivative liabilities 436 - 436 100 %
Gain on troubled debt restructurings - (1,862 ) 1,862 -100 %
Loss on extinguishment of debt - 41 (41 ) -100 %
Other expense, net 1 8 (7 ) -88 %
Total other expense (income), net 426 (1,494 ) 1,920 -129 %
Net (loss) income $ (2,660 ) $ (741 ) $ (1,919 ) -259 %

Revenue

Total revenue increased by $0.8 million, or 478%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The increase was attributable to a $0.8 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes.

Cost of Revenue

Cost of revenue was $1.4 million for the three months ended September 30, 2026, compared to $0.4 million for the three months ended September 30, 2025, an increase of $1.0 million, or 247%. The increase was primarily driven by a $0.5 million increase in software and hosting costs associated with operating and scaling the Company's AI-enabled real-world data platform, a $0.4 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.1 million increase in personnel costs due to headcount growth.

General and Administrative

General and administrative expenses were $1.2 million for the three months ended September 30, 2026, compared to $1.4 million for the three months ended September 30, 2025, a decrease of $0.2 million, or 15%. The decrease was primarily attributable to a $0.4 million decrease in professional fees, largely due to lower consulting and legal costs, which is partially offset by a $0.2 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026,

Sales and Marketing

Sales and marketing expenses for the three months ended September 30, 2026, were generally consistent with sales and marketing expenses for the three months ended September 30, 2025.

Research and Development

Research and development expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.3 million for the three months ended September 30, 2025, an increase of $0.1 million, or 31%. The increase was primarily attributable to a $0.1 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026.

Interest Expense

Interest expense for the three months ended September 30, 2026 was generally consistent with interest expense for the three months ended September 30, 2025.

Change in Fair Value of Warrants

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

Change in Fair Value of Crypto Assets - Bitcoin

The change in fair value of crypto assets - Bitcoin during the three months ended September 30, 2025, reflected fluctuations in the price of Bitcoin. There was no corresponding change in fair value during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

Realized Gain on Sale of Crypto Assets - Bitcoin

The realized gain on sale of crypto assets - Bitcoin during the three months ended September 30, 2025, reflected the difference between the carrying value of Bitcoin and its market price upon sale. There was no corresponding realized gain during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

Change in Fair Value of SEPA Derivative Liabilities

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company's projected stock price over the applicable commitment period. The change in fair value during the three months ended September 30, 2026, related to the 2026 SEPA, while the change in fair value during the three months ended September 30, 2025, related to the 2024 SEPA.

Gain on Troubled Debt Restructurings

Gain on troubled debt restructurings during the three months ended September 30, 2025 was primarily driven by restructured trade payables with two separate vendors which resulted in a gain of $1.9 million. During the three months ended September 30, 2026, we did not restructure any of our debt or trade payables.

Comparison of the Nine Months Ended September 30, 2026 and 2025

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

Nine Months Ended September 30, Change
2026 2025 $ %
Revenue
Subscription revenue $ - $ 105 $ (105 ) -100 %
Data delivery revenue 1,410 363 1,047 288 %
Total revenue 1,410 468 942 201 %
Cost of revenue 2,928 1,136 1,792 158 %
Gross margin (1,518 ) (668 ) (850 ) 127 %
Operating expenses
General and administrative 3,439 3,999 (560 ) -14 %
Sales and marketing 1,031 846 185 22 %
Research and development 1,059 1,072 (13 ) -1 %
Total operating expenses 5,529 5,917 (388 ) -7 %
Loss from operations (7,047 ) (6,585 ) (462 ) 7 %
Other (income) expense, net
Interest expense 27 59 (32 ) -54 %
Change in fair value of warrants (66 ) 23 (89 ) -387 %
Change in fair value of convertible notes - (1,285 ) 1,285 -100 %
Change in fair value of crypto assets - Bitcoin (147 ) 782 (929 ) -119 %
Realized loss (gain) on sale of crypto assets - Bitcoin 234 (899 ) 1,133 -126 %
Change in fair value of 2024 SEPA derivative liabilities (245 ) (32 ) (213 ) 666 %
Change in fair value of 2026 SEPA derivative liabilities 436 - 436 100 %
Gain on troubled debt restructurings - (5,569 ) 5,569 -100 %
Loss on extinguishment of debt - 41 (41 ) -100 %
Other (income) expense, net (1 ) (44 ) 43 -98 %
Total other (income) expense, net 238 (6,924 ) 7,162 -103 %
Net (loss) income $ (7,285 ) $ 339 $ (7,624 ) -2249 %

Revenue

Total revenue increased by $0.9 million, or 201%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.0 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes. This growth was partially offset by a $0.1 million decrease in subscription revenue due to the decommissioning of the BEAM platform in May 2025.

Cost of Revenue

Cost of revenue was $2.9 million for the nine months ended September 30, 2026, compared to $1.1 million for the nine months ended September 30, 2025, an increase of $1.8 million, or 158%. The increase was primarily driven by a $1.1 million increase in software and hosting costs associated with operating and scaling the Company's AI-enabled real-world data platform, a $0.5 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.2 million increase in personnel costs due to headcount growth.

General and Administrative

General and administrative expenses were $3.4 million for the nine months ended September 30, 2026, compared to $4.0 million for the nine months ended September 30, 2025, representing a decrease of $0.6 million, or 14%. The decrease was primarily attributable to a $1.0 million reduction in professional fees, primarily due to lower legal, consulting, and other professional service costs, and a $0.1 million decrease in other general and administrative expenses. These decreases were partially offset by a $0.5 million increase in share-based compensation expense related to equity awards granted during 2025 and 2026 and a $0.1 million increase in salaries and related personnel costs resulting from headcount growth.

Sales and Marketing

Sales and marketing expenses were $1.0 million for the nine months ended September 30, 2026, compared to $0.8 million for the nine months ended September 30, 2025, representing an increase of $0.2 million, or 22%. The increase was primarily attributable to a $0.1 million increase in personnel costs due to headcount growth and a $0.1 million increase in consulting costs resulting from business development initiatives intended to support growth of the Company's iRWD platform.

Research and Development

Research and development expenses for the nine months ended September 30, 2026, were generally consistent with research and development expenses for the nine months ended September 30, 2025.

Interest Expense

Interest expense for the nine months ended September 30, 2026 was generally consistent with interest expense for the nine months ended September 30, 2025.

Change in Fair Value of Warrants

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

Change in Fair Value of Convertible Notes

The change in fair value of convertible notes is composed of the re-measurement adjustment for the PIPE Notes and Yorkville Note which are carried at fair value. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock. Both instruments were converted or repaid in the second quarter of 2025; therefore, no re-measurement adjustment was required for the nine months ended September 30, 2026.

Change in Fair Value of Crypto Assets - Bitcoin

The change in fair value of crypto assets - Bitcoin during the nine months ended September 30, 2026 and 2025 reflected fluctuations in the price of Bitcoin.

Realized Loss (Gain) on Sale of Crypto Assets - Bitcoin

The realized loss (gain) on sale of crypto assets - Bitcoin during the nine months ended September 30, 2026 and 2025 reflected the difference between the carrying value of Bitcoin and its market price upon sale.

Change in Fair Value of SEPA Derivative Liabilities

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company's projected stock price over the applicable commitment period. For the nine months ended September 30, 2026, the change in fair value included amounts related to both the 2024 SEPA and the 2026 SEPA, whereas the change in fair value for the nine months ended September 30, 2025, related solely to the 2024 SEPA.

Gain on Troubled Debt Restructurings

Gain on troubled debt restructurings during the nine months ended September 30, 2025 was primarily driven by our settlement of deferred underwriter fees which resulted in a gain of $2.8 million. In addition, we restructured trade payables with five separate vendors leading to an additional gain of $2.8 million. During the nine months ended September 30, 2026, we did not restructure any of our debt or trade payables.

Liquidity and Capital Resources

As of September 30, 2026, our principal sources of liquidity were proceeds from related party investors and the 2024 SEPA.

The following table shows net cash and cash equivalents used in operating activities, net cash and cash equivalents used in investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:

Nine Months Ended September 30,
2026 2025
Net cash provided by (used in)
Operating activities $ (4,839 ) $ (5,455 )
Investing activities 407 2,358
Financing activities 3,984 3,074

Operating Activities

Our net cash and cash equivalents used in operating activities consists of net loss adjusted for certain non-cash items, including depreciation and amortization, stock-based compensation expense, changes in fair value of liability classified financial instruments, as well as changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation. This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the fulfillment of the performance obligation.

During the nine months ended September 30, 2026, we used $4.8 million of cash in operating activities, primarily resulting from our net loss of $7.3 million, offset by non-cash charges of $1.6 million and cash provided by changes in our operating assets and liabilities of $0.9 million.

During the nine months ended September 30, 2025, we used $5.5 million of cash in operating activities, primarily resulting from non-cash charges of $6.3 million, offset by our net income of $0.3 million and cash provided by changes in our operating assets and liabilities of $0.5 million.

Investing Activities

Our investing activities have consisted primarily of property and equipment purchases and Bitcoin purchases and sales.

During the nine months ended September 30, 2026, net cash provided by investing activities was $0.4 million, primarily consisting of proceeds from Bitcoin sales of $0.4 million.

During the nine months ended September 30, 2025, net cash provided by investing activities was $2.4 million, primarily consisting of proceeds from Bitcoin sales of $4.8 million offset by Bitcoin purchases of $2.4 million.

Financing Activities

During the nine months ended September 30, 2026, net cash provided by financing activities was $4.0 million, consisting of $3.4 million in net proceeds from related party investments and $1.0 million in net proceeds from the 2024 SEPA, partially offset by debt repayments of $0.4 million.

During the nine months ended September 30, 2025, net cash provided by financing activities was $3.1 million, consisting of $1.7 million in net proceeds from related party investments and $2.5 million in net proceeds from private placements, partially offset by aggregate repayments of $1.1 million of debt and deferred underwriter fees.

Contractual Obligations and Commitments and Going Concern Outlook

Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company's recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company's ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company's ability to continue as a going concern.

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all.

The following table summarizes our material cash requirements as of September 30, 2026:

Payments due in:
Total Less than 1 year 1-3 years
Accounts payable & accrued expenses $ 4,504 $ 4,504 $ -
Loans payable 563 464 99
$ 5,067 $ 4,968 $ 99

Critical Accounting Policies and Estimates

Our management's discussion and analysis of financial condition and results of operations is based on our consolidated financial statements which have been prepared in accordance with GAAP. In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results of operations and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates.

For a discussion of our critical accounting estimates, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Form 10-K, the notes to our audited financial statements appearing in the Form 10-K, and the notes to the financial statements appearing elsewhere in this Report. Except as described in this Report, there have been no material changes to these critical accounting policies and estimates through September 30, 2026 from those discussed in the Form 10-K.

Recently Issued and Adopted Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements included elsewhere in this Report.

Onemednet Corporation published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 16, 2026 at 21:53 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]